Xintela AB (publ) (STO:XINT)
Sweden · Delayed Price · Currency is SEK 0.2340
-0.0040 (-1.68%)
Apr 30, 2026, 12:35 PM CET
Xintela AB Market Cap
Xintela AB has a market cap or net worth of 201.54 million as of April 30, 2026. Its market cap has decreased by -16.15% in one year.
Market Cap
201.54M
Enterprise Value
178.33M
Revenue
2.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.23
Market Cap Chart
Since March 22, 2016, Xintela AB's market cap has increased from 103.68M to 201.54M, an increase of 94.38%. That is a compound annual growth rate of 6.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 29, 2026 | 204.98M | 3.17% |
| Dec 30, 2025 | 198.68M | 5.85% |
| Dec 30, 2024 | 187.69M | 26.87% |
| Dec 29, 2023 | 147.94M | -1.74% |
| Dec 30, 2022 | 150.56M | -26.24% |
| Dec 30, 2021 | 204.12M | 2.23% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bio-Works Technologies AB | 308.22M |
| Mendus AB | 300.00M |
| Initiator Pharma | 221.79M |
| Isofol Medical AB | 214.73M |
| Xbrane Biopharma AB | 206.05M |
| Active Biotech AB | 163.44M |
| AlzeCure Pharma AB | 158.58M |
| Diamyd Medical AB | 158.08M |